BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31086093)

  • 1. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study.
    Passardi A; Scarpi E; Neri E; Parisi E; Ghigi G; Ercolani G; Gardini A; La Barba G; Pagan F; Casadei-Gardini A; Valgiusti M; Ferroni F; Frassineti GL; Romeo A
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31086093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer.
    Milandri C; Polico R; Garcea D; Passardi A; Gardini A; Romeo A; Scarpi E; Rosetti P; Ridolfi L; La Barba G; Ricci M; Amadori D
    Hepatogastroenterology; 2011; 58(106):599-603. PubMed ID: 21661438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies.
    Passardi A; Rapposelli IG; Scarpi E; Sullo FG; Bartolini G; Neri E; Ghigi G; Tontini L; Ercolani G; Monti M; Ruscelli S; Matteucci L; Valgiusti M; Frassineti GL; Romeo A
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer.
    Shi Z; Yang J; Kong W; Qiu X; Lu C; Liu J; Liu B; Du J
    Front Oncol; 2022; 12():782730. PubMed ID: 35299738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
    Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
    J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J; Merl M; Lee MX; Kaley K; Saif MW
    Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
    Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
    Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen.
    Cui XY; Li XC; Cui JJ; Wu XS; Zou L; Song XL; Ren T; Zhu YD; Li HF; Yang Y; Liu K; Han XS; Jia ZY; Wu WG; Wang XA; Gong W; Wang LW; Li ML; Liu YB
    Hepatobiliary Surg Nutr; 2021 Aug; 10(4):498-506. PubMed ID: 34430528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
    Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
    Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer.
    Woo SM; Lee SH; Yoo JW; Yang KY; Seo JG; Park JK; Hwang JH; Lee WJ; Ryu JK; Kim YT; Yoon YB
    Gut Liver; 2013 Sep; 7(5):594-8. PubMed ID: 24073318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma.
    Maximous DW; Abdel-Wanis ME; El-Sayed MI; Abd-Elsayed AA
    Int Arch Med; 2009 Mar; 2(1):7. PubMed ID: 19327152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.